Creative medical technology holdings receives notice of allowance for immcelz™ for treatment of heart failure and/or post infarct pathological remodeling

Phoenix, july 11, 2025 (globe newswire) -- creative medical technology holdings, inc. (nasdaq: celz) (“creative medical” or the “company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a notice of allowance from the united states patent and trademark office (uspto) for a u.s. patent application titled, “treatment of heart failure and/or post infarct pathological remodeling by ex vivo reprogrammed immune cells.”
CELZ Ratings Summary
CELZ Quant Ranking